Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

Table 5 Univariate logistic regression model with associated factors for clinical and endoscopic remission at week 52 of treatment in UC patients

	Clinical remission			Endoscopic remission
	Odds Ratio	95% Confidence interval	P value	Odds Ratio	95% Confidence interval	P value
Age (y)	1.052	1.026–1.080	0.0001	1.008	0.990–1.026	0.3998
Gender (female vs. male)	1.481	0.801–2.739	0.2105	1.493	0.910–2.449	0.1129
BMI (kg/m²)	1.027	0.958–1.101	0.4596	1.006	0.955–1.060	0.8291
Active smoking (yes x no)	1.741	0.503–6.021	0.3813	1.537	0.627–3.770	0.3478
Time between diagnosis and onset of anti-TNF (y)	1.035	0.970–1.105	0.2954	0.987	0.942–1.035	0.6015
Presence of EIM	1.110	0.579–2.129	0.7538	1.195	0.711–2.007	0.5011
Corticosteroid at baseline	0.509	0.235–1.102	0.0868	0.648	0.368–1.140	0.1320
Azathioprine use	1.105	0.528–2.314	0.7908	1.158	0.641–2.093	0.6274
Total Mayo score at baseline (points)	0.866	0.755–0.994	0.0401	1.014	0.917–1.121	0.7879
No previous use of biological therapy	2.903	1.423–5.922	0.0034	2.000	1.056–3.787	0.0333
Anti-TNF therapy (IFX vs. ADA)	1.980	1.040–3.759	0.0378	1.0941	0.6325–1.8939	0.7472
Clinical response at week 8	1.848	0.986–3.465	0.0555	1.770	1.059–2.957	0.0293
Clinical response at week 26	4.778	2.208–10.339	< 0.0001	7.341	3.228–16.695	< 0.0001
Endoscopic remission at week 26	4.909	2.295–10.500	< 0.0001	8.280	4.138–16.571	< 0.0001
Loss of response (No vs. Yes)	5.042	2.506–10.146	< 0.0001	6.489	3.701–11.379	< 0.0001
Drug optimization (No vs. Yes)	4.913	2.458–9.819	< 0.0001	6.355	3.651–11.064	< 0.0001

ISSN: 1471-230X